Landiolol reduces hemodynamic responses to bronchoscopy-assisted suctioning in intubated ICU patients

Landiolol is an ultra-short-acting β(1)-selective antagonist developed in Japan that was recently approved for the treatment of tachycardia in intensive care units (ICUs). This study investigated the protective effects of landiolol against the cardiovascular responses during bronchoscopic endotrache...

Descripción completa

Detalles Bibliográficos
Autores principales: Tochikubo, Junpei, Adachi, Yushi U, Ejima, Tadashi, Numaguchi, Atsushi, Matsuda, Naoyuki, Sato, Shigehito, Shiiya, Norihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267460/
https://www.ncbi.nlm.nih.gov/pubmed/25520823
http://dx.doi.org/10.1186/2052-0492-2-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267460/
https://www.ncbi.nlm.nih.gov/pubmed/25520823
http://dx.doi.org/10.1186/2052-0492-2-6

Ejemplares similares